Researchers Present Results for Topical AMD Eye Drop

A new phase 1 study shows that the investigational eye drop CG-P5 achieves results comparable to current injection-based treatments.

Updated on Oct. 27, 2026 in Biotech

Bold flat-color editorial illustration showing a medicine dropper bottle, representing a new medical treatment study. — Researchers presented phase 1 study results for CG-P5, a new topical eye drop for wet age-related macular degeneration, at an ophthalmology meeting. AI Illustration. Upload story photo >

Live Poll

Do you believe new medical research leads to better health outcomes for your own healthcare needs?

Researchers recently presented phase 1 study results at the American Academy of Ophthalmology meeting for CG-P5, a topical peptide eye drop. The treatment showed promising safety and pharmacodynamic signals in patients with wet age-related macular degeneration.

Why it matters

Up to 40% of patients currently treated for wet AMD do not meet treatment expectations, creating a need for more effective or accessible options. Topical drops are expected to significantly reduce the treatment burden for those currently requiring regular injections.

The 84-day phase 1 study reported zero treatment-related serious adverse events across all trial arms. Patients treated with CG-P5 demonstrated improvements in intraretinal fluid and hyperreflective foci.

The players

American Academy of Ophthalmology

This professional medical association hosts annual meetings where ophthalmologists and researchers gather to discuss advancements in eye care.

Erie Retina Research

This Pennsylvania-based clinical research facility focuses on investigating treatments for retinal diseases.

The details

The study utilized a randomized design to compare the safety and efficacy of CG-P5, a 2 mg dose of aflibercept, and a placebo in patients with treatment-experienced wet age-related macular degeneration. Researchers highlighted that the eye drops offer a potential alternative to invasive ocular injections.

Day 56: The point where CG-P5 and aflibercept outcomes were matched.
84 days: The total duration of the phase 1 study.

The Tech Race

This research follows the path established by the development of standard anti-VEGF injection therapies by exploring non-invasive alternatives. It positions topical delivery as a potential replacement for more cumbersome legacy systems in ophthalmology.

The potential approval of a topical eye drop could eventually replace the need for frequent, recurring clinic visits for eye injections. Patients would experience less discomfort and greater autonomy in managing their treatment schedules for wet AMD.

The takeaway

Topical delivery methods represent a shift toward patient-centered care in chronic retinal disease management. Readers should consult their ophthalmologist to monitor when new clinical trial results might translate into approved treatment options.